Photo by nampoh from unsplash
From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal… Click to show full abstract
From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal function. The aim of this study was to assess the efficacy and safety of this combination that have not yet been addressed in patients undergoing dialysis.
Keywords:
genotype chronic;
efficacy safety;
ombitasvir paritaprevir;
paritaprevir ritonavir;
chronic hepatitis
Journal Title: Hepatology Research
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology Research
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!